SEC Form 4 · accession 0001636282-26-000102
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey W. Albers
Director
Period of report
Aug 7, 2026
Accepted (ET)
Aug 10, 2026 · 9:31 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2026 | M | 5,000 | $10.39 | A | 5,000 | D | |
| Common StockF2 | Aug 7, 2026 | S | 5,000 | $104.47 | D | 0 | D | |
| Common StockF3 | Aug 7, 2026 | S | 8,000 | $104.38 | D | 19,360 | I | By Sessions LLC |
| Common StockF4 | Aug 7, 2026 | S | 10,000 | $104.68 | D | 9,360 | I | By Sessions LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $10.39 | Aug 7, 2026 | M | 5,000 | D | — | Nov 22, 2033 | Common Stock | 5,000 | 45,000 | D |
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.